Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prantesh Jain

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical Lung Cancer|June 15, 2024
Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?Muhammad Awidi, Angel Mier-Hicks, Stuthi Perimbeti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 23, 2020
Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System AnalysisAvirup Guha, Daniel Addison, Prantesh Jain, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic featuresMohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, et al.
NPJ Precision Oncology|March 18, 2026
Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC)Cristian Barrera, Prantesh Jain, Germán Corredor, et al.
Research and Practice in Thrombosis and Haemostasis|April 24, 2019
Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology settingGirish Kunapareddy, Benjamin Switzer, Prantesh Jain, et al.
Cancer Medicine|May 13, 2021
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registriesAvirup Guha, Prantesh Jain, Michael G Fradley, et al.
ESC Heart Failure|May 13, 2021
Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantationAvirup Guha, Cesar Caraballo, Prantesh Jain, et al.
JCO Oncology Practice|August 22, 2024
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint InhibitorsAlfredo V Chua, Jennifer Delmerico, Haiyang Sheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2022
Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple CancersNathaniel Braman, Prateek Prasanna, Kaustav Bera, et al.
Journal of the National Cancer Institute|November 19, 2024
Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metforminRandall J Smith, Robert Zollo, Sukumar Kalvapudi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Lung Cancer|June 15, 2024
Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?Muhammad Awidi, Angel Mier-Hicks, Stuthi Perimbeti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 23, 2020
Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System AnalysisAvirup Guha, Daniel Addison, Prantesh Jain, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic featuresMohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, et al.
NPJ Precision Oncology|March 18, 2026
Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC)Cristian Barrera, Prantesh Jain, Germán Corredor, et al.
Research and Practice in Thrombosis and Haemostasis|April 24, 2019
Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology settingGirish Kunapareddy, Benjamin Switzer, Prantesh Jain, et al.
Cancer Medicine|May 13, 2021
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registriesAvirup Guha, Prantesh Jain, Michael G Fradley, et al.
ESC Heart Failure|May 13, 2021
Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantationAvirup Guha, Cesar Caraballo, Prantesh Jain, et al.
JCO Oncology Practice|August 22, 2024
Under-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint InhibitorsAlfredo V Chua, Jennifer Delmerico, Haiyang Sheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2022
Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple CancersNathaniel Braman, Prateek Prasanna, Kaustav Bera, et al.
Journal of the National Cancer Institute|November 19, 2024
Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metforminRandall J Smith, Robert Zollo, Sukumar Kalvapudi, et al.
Pageof 3